410 results on '"Sardesai, Niranjan Y."'
Search Results
2. Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost
3. Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine
4. Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus
5. A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity
6. Vaccines in Research and Development: New Production Platforms and New Biomolecular Entities for New Needs
7. Data from A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge
8. Supplementary Data from A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge
9. Supplementary Figures from A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge
10. Supp Figures from Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy
11. Supp Figure Legends from Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy
12. Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus
13. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
14. Recombinant rubella vectors elicit SIV Gag-specific T cell responses with cytotoxic potential in rhesus macaques
15. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody
16. Activated CD4⁺CCR5⁺ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques
17. Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques
18. Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses
19. Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine
20. A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus
21. Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery
22. DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge
23. Plasmodium inui Infection Reduces the Efficacy of a Simian Immunodeficiency Virus DNA Vaccine in a Rhesus Macaque Model Through Alteration of the Vaccine-Induced Immune Response
24. Protocols for Developing Novel Chikungunya Virus DNA Vaccines
25. Multivalent Smallpox DNA Vaccine Delivered by Intradermal Electroporation Drives Protective Immunity in Nonhuman Primates Against Lethal Monkeypox Challenge
26. DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections
27. Safety, bioavailability, and pharmacokinetics of VGX-1027—A novel oral anti-inflammatory drug in healthy human subjects
28. Vaccines in Research and Development: New Production Platforms and New Biomolecular Entities for New Needs
29. REVERSE VACCINOLOGY IDENTIFIED PROMISING VACCINE CANDIDATES FOCUSING RESPONSES TO RELATIVELY CONSERVED REGIONS ASSOCIATED WITH CONTROL OF VIREMIA: O6.10
30. DNA Vaccination in Skin Enhanced by Electroporation
31. Clinical Development of Intramuscular Electroporation: Providing a “Boost” for DNA Vaccines
32. A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generation
33. VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus
34. Tolerability of intramuscular and intradermal delivery by CELLECTRA® adaptive constant current electroporation device in healthy volunteers
35. Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques
36. Electroporation mediated DNA vaccination directly to a mucosal surface results in improved immune responses
37. Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer
38. Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice
39. IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques
40. Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen
41. DNA VACCINATION WITH ELECTROPORATION CAN BE CONTINUALLY BOOSTED AND OUTPERFORMS THE AD5 VECTOR PLATFORM: Abstract #67
42. ESTIMATING THE EFFECTORT CELL RESPONSE TO DNAVACCINATION IN RHESUS MACAQUES AND HUMANS: Abstract #63
43. How will diagnostics create new opportunities for prophylactic and therapeutic vaccines?: 2011 phacilitate vaccine forum, Washington DC Day 2, afternoon plenary session—January 25, 2011
44. Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses
45. Piezoelectric permeabilization of mammalian dermal tissue for in vivo DNA delivery leads to enhanced protein expression and increased immunogenicity
46. Robust antibody and cellular responses induced by DNA-only vaccination for HIV
47. Abstract B67: Synthetic DNA multi-neoantigen vaccine drives predominately MHC class I CD8+ T cell-mediated effector immunity impacting tumor challenge
48. Efficient 50S ribosome-catalyzed peptide bond synthesis with an aminoacyl minihelix
49. Analysis of the Potential for HIV-1 Vpr as an Anti-Cancer Agent
50. DNA recognition by metal-peptide complexes containing the recognition helix of the phage 434 repressor
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.